Today, the World Anti-Doping Agency (WADA) published the following WADA-accredited laboratory guidelines, which take effect immediately.
- The Guideline for Conducting and Reporting Subcontracted Analysis and Further Analysis for Doping Control, version 2.0, dated June 2018 has been developed to ensure a harmonized approach in the analysis and reporting of samples, which are shipped to another laboratory for subcontracted analyses or for further analysis of long-term stored samples [as described in the International Standard for Laboratories (ISL)]. This Guideline also provides direction on several scenarios that may require that a sample be shipped between laboratories, including how to report the results into WADA’s Anti-Doping Administration and Management System (ADAMS).
- The revised Guideline for TUE Enquiries by Accredited Laboratories, version 2.0, dated June 2018, which assists laboratories in reporting Presumptive Adverse Analytical Findings exclusively for the S.3. Beta-2 Agonists and S.9. Glucocorticoids drug classes; and, in enquiring with the relevant Testing Authority and/or Results Management Authority about the existence of an approved Therapeutic Use Exemption (TUE) before performing confirmation analyses.